Zoledronic acid - Osteoporosis
You are here : Home > Formulary Search > Zoledronic acid - Osteoporosis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
- Intravenous infusion
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
Guidelines (Local)
Guidelines (Local)
Guidelines (Local)
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Zoledronic acid
Indication :
Osteoporosis
Group Name :
Keywords :
Zoledronate
Brand Names Include :
Aclasta
Important Information :
5mg annual infusion
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5
Other Indications
Below are listed other indications that Zoledronic acid is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Osteoporosis.
Committee Recommendations (2)
21 Nov 19 -
Surrey Downs MOG
SDCCG LOCAL INFORMATION - Epsom & St Helier and the Surrey Downs CCG MOG have agreed an information sheet for GPs in relation to the assessment and management of fragility fracture patients on IV Zoledronic acid.
See SDCCG document below
25 Sep 09 -
Surrey Medicines Commissioners Group
Zoledronic acid (Aclasta) - To use only on the recommendation of a Consultant Rheumatologist or Geriatrician in patients with osteoporosis for whom a bisphosphonate is the most appropriate line of treatment and who are unsuitable for or unable to tolerate oral bisphosphonates for osteoporosis or who are unable to comply with them and for patients with fractures despite oral bisphosphonates. It should be administered only in a place with the required clinical governance systems in place (training of staff, IV administration protocols etc).